舒利迭联合无创通气对老年慢性阻塞性肺疾病急性加重期并Ⅱ型呼吸衰竭的疗效分析

Analysis of curative effect of Seretide combined with noninvasive ventilation for senile patients with acute exacerbation of chronic obstructive pulmonary disease and type Ⅱ respiratory failure

目的探讨沙美特罗替卡松粉吸入剂(舒利迭)联合无创通气治疗老年慢性阻塞性肺疾病急性加重期合并Ⅱ型呼吸衰竭的疗效。方法 90例老年慢性阻塞性肺疾病急性加重期合并Ⅱ型呼吸衰竭患者,按随机数字表法分为观察组和对照组,各45例。对照组给予常规治疗联合无创通气治疗,观察组在对照组基础上联合舒利迭治疗。对比两组患者的第一秒用力呼气容积(FEV1)、FEV1/用力肺活量(FEV1/FVC)、FEV1占预计值百分比(FEV1%)指标水平。结果治疗3 d后,两组患者的FEV1、FEV1/FVC、FEV1%指标水平均较治疗前升高,且观察组治疗3 d后FEV1(1.92±0.54)L、FEV1/FVC(65.32±5.97)%、FEV1%(67.52±6.54)%高于对照组[(1.73±0.46)L、(57.99±5.72)%、(58.14±5.12)%],差异均具有统计学意义(P<0.05)。结论舒利迭联合无创通气治疗老年慢性阻塞性肺疾病急性加重期合并Ⅱ型呼吸衰竭效果显著。

Objective To explore the curative effect of salmeterol xinafoate and fluticasone propionate powder for inhalation （Seretide） combined with noninvasive ventilation for patients with acute exacerbation of chronic obstructive pulmonary disease and type Ⅱ respiratory failure. Methods A total of 90 patients with acute exacerbation of chronic obstructive pulmonary disease and type H respiratory failure were divided by random number table method into observation group and control group, with 45 cases in each group. The control group received conventional therapy combined with noninvasive ventilation for treatment, and the observation group received Seretide on the basis of the control group for treatment. Comparison were made on forced expiratory volume in 1 second percentage （FEV1）, FEV1/forced vital capacity （FEV1/FVC） and forced expiratory volume in 1 second percentage of expected value （FEV1%） level in two groups. Results After 3 d of treatment, both groups had higher FEV1, FEV1/FVC and FEV1% level than before treatment, and the observation group had higher FEV1 as （1.92 ± 0.54） L, FEV1/FVC as （65.32 ± 5.97）% and FEV1%（67.52 ± 6.54）% after 3 d of treatment than the control group [（1.73 ± 0.46） L, （57.99 ± 5.72）% and （58.14 ± 5.12）% ]. Their difference had statistical significance （P〈0.05）. Conclusion Combination of Seretide and noninvasive ventilation shows significant effect in treating senile patients with acute exacerbation of chronic obstructive pulmonary disease and type Ⅱ respiratory failure.